Related references
Note: Only part of the references are listed.Machine learning for prediction of cutaneous adverse events in patients receiving antiePD-1 immunotherapy
Ryan T. Lewinson et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review
Shaheen Khan et al.
SEMINARS IN CANCER BIOLOGY (2020)
Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors
Sadal Refae et al.
INVESTIGATIONAL NEW DRUGS (2020)
BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors
Omar Hasan Ali et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors
Chiaki Kurimoto et al.
CANCER SCIENCE (2020)
Mechanisms of checkpoint inhibition-induced adverse events
P. Urwyler et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2020)
Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry
Rik J. Verheijden et al.
CLINICAL CANCER RESEARCH (2020)
B cells are associated with survival and immunotherapy response in sarcoma
Florent Petitprez et al.
NATURE (2020)
Tertiary lymphoid structures improve immunotherapy and survival in melanoma
Rita Cabrita et al.
NATURE (2020)
B cells and tertiary lymphoid structures promote immunotherapy response
Beth A. Helmink et al.
NATURE (2020)
Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors
Lihong Peng et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis
Mitchell S. von Itzstein et al.
CLINICAL CHEMISTRY (2020)
Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor-induced secondary adrenal insufficiency
Seiichi Yano et al.
EUROPEAN JOURNAL OF CANCER (2020)
Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer
Zia Khan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
MicroRNA-146a regulates immune-related adverse events caused by immune checkpoint inhibitors
Dominik Marschner et al.
JCI INSIGHT (2020)
Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade
Chipman R. G. Stroud et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2019)
Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab
Jun Oyanagi et al.
LUNG CANCER (2019)
BASELINE TSH LEVEL IS ASSOCIATED WITH RISK OF ANTI-PD-1-INDUCED THYROID DYSFUNCTION
Rena M. Pollack et al.
ENDOCRINE PRACTICE (2019)
Development of immune checkpoint therapy for cancer
Jill M. Fritz et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2019)
Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors
Alberto Pavana et al.
ONCOLOGIST (2019)
Management of immune related adverse events induced by immune checkpoint inhibition
Andreas Teufel et al.
CANCER LETTERS (2019)
C-reactive protein as an early marker of immune-related adverse events
Amir-Reza Abolhassani et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities
Salahaldin A. Tahir et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab
Yeonghee Eun et al.
SCIENTIFIC REPORTS (2019)
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Satya Das et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Immune dysregulation in cancer patients developing immune-related adverse events
Shaheen Khan et al.
BRITISH JOURNAL OF CANCER (2019)
Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study
Maria Pia Pistillo et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy
Su Y. Lim et al.
CLINICAL CANCER RESEARCH (2019)
Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors
Omar Hasan Ali et al.
EUROPEAN JOURNAL OF CANCER (2019)
Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies
Yoshiyuki Nakamura et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2019)
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Bertrand Routy et al.
SCIENCE (2018)
Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients
Sander Bins et al.
BRITISH JOURNAL OF CANCER (2018)
The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy
Vancheswaran Gopalakrishnan et al.
CANCER CELL (2018)
CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy
Ryuma Tokunaga et al.
CANCER TREATMENT REVIEWS (2018)
The microbiome and autoimmunity: a paradigm from the gut-liver axis
Bo Li et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2018)
Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
Angeliki Stamatouli et al.
DIABETES (2018)
Biomarker definitions and their applications
Robert M. Califf
EXPERIMENTAL BIOLOGY AND MEDICINE (2018)
Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
Kristian M. Hargadon et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Early B cell changes predict autoimmunity following combination immune checkpoint blockade
Rituparna Das et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors
Michael F. Gowen et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade
Sara Valpione et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Vyara Matson et al.
SCIENCE (2018)
Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis
Danielle Benedict Sacdalan et al.
ONCOTARGETS AND THERAPY (2018)
Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study
Taku Fujimura et al.
Oncotarget (2018)
Immune Dysregulation in Cancer Patients Undergoing Immune Checkpoint Inhibitor Treatment and Potential Predictive Strategies for Future Clinical Practice
Ronald Anderson et al.
FRONTIERS IN ONCOLOGY (2018)
Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab
Shiro Kimbara et al.
CANCER SCIENCE (2018)
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis
Daniel Y. Wang et al.
JAMA ONCOLOGY (2018)
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer
J. C. Osorio et al.
ANNALS OF ONCOLOGY (2017)
Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire
David Y. Oh et al.
CANCER RESEARCH (2017)
Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)
Frederic Bigot et al.
EUROPEAN JOURNAL OF CANCER (2017)
Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities
Clelia Coutzac et al.
JOURNAL OF CROHNS & COLITIS (2017)
Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab
Yasuhiro Fujisawa et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2017)
Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-α is a biomarker of nivolumab recativity
Ryota Tanaka et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2017)
Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors
Adam Diehl et al.
ONCOTARGET (2017)
Eosinophils in Autoimmune Diseases
Nicola L. Diny et al.
FRONTIERS IN IMMUNOLOGY (2017)
Interleukin-17 acts as double-edged sword in anti-tumor immunity and tumorigenesis
Xin Qian et al.
CYTOKINE (2017)
Predictive Factors of Nivolumab-induced Hypothyroidism in Patients with Non-small Cell Lung Cancer
Toshiya Maekura et al.
IN VIVO (2017)
Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review
L. Khoja et al.
ANNALS OF ONCOLOGY (2017)
The Challenge for Development of Valuable Immuno-oncology Biomarkers
Janice M. Mehnert et al.
CLINICAL CANCER RESEARCH (2017)
Immunological Characteristics of Colitis Associated with Anti-CTLA-4 Antibody Therapy
Giorgos Bamias et al.
CANCER INVESTIGATION (2017)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2017)
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab
N. Chaput et al.
ANNALS OF ONCOLOGY (2017)
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
Sumit K. Subudhi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
The cancer immunogram
Christian U. Blank et al.
SCIENCE (2016)
Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
Krista Dubin et al.
NATURE COMMUNICATIONS (2016)
Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab
V. Damuzzo et al.
ONCOIMMUNOLOGY (2016)
IL-6 as a keystone cytokine in health and disease
Christopher A. Hunter et al.
NATURE IMMUNOLOGY (2015)
Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
Ahmad A. Tarhini et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee et al.
BLOOD (2014)
Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events
Vafa Shahabi et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Toward a cytokine-based disease taxonomy
Georg Schett et al.
NATURE MEDICINE (2013)
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Targeting IL-17and TH17 cells in chronic inflammation
Pierre Miossec et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Increased Risk of Breast Cancer Associated with CC Genotype of Has-miR-146a Rs2910164 Polymorphism in Europeans
Hai Lian et al.
PLOS ONE (2012)
Organ specific-autoantibodies: Their role as markers and predictors of disease
Piercarlo Sarzi-Puttini et al.
AUTOIMMUNITY (2008)
Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent
SH Jaber et al.
ARCHIVES OF DERMATOLOGY (2006)
Share Paper
